{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:18:21Z","timestamp":1795141101179,"version":"4.10.3"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare functional and anatomical outcomes of combining intravitreal dexamethasone implant (DEX-I) (Ozurdex) with navigated subthreshold yellow (577 nm) micropulse laser (subthreshold micropulse laser treatment [SMLT]) versus dexamethasone monotherapy in diabetic macular edema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this prospective randomized study, 80 eyes with center-involving diabetic macular edema were allocated to two groups: 40 eyes received DEX-I followed 4 weeks later by navigated SMLT (DEX-I + SMLT), and 40 eyes received DEX-I alone (DEX-I). Best-corrected visual acuity (Early Treatment Diabetic Retinopathy Study - ETDRS letters), central subfield thickness, and ETDRS subfield thicknesses were measured at baseline and at 2, 4, 6, 9, and 12 months. Reinjection-free survival was analyzed over 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At 6 months, mean best-corrected visual acuity improvement was greater in the DEX-I + SMLT group than in the DEX-I monotherapy group (6.2 \u00b1 5.1 vs. 4.1 \u00b1 6.4 letters;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03), and this difference persisted at 12 months (5.8 \u00b1 6.5 vs. 3.6 \u00b1 6.8 letters;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.05). Mean central subfield thickness was lower in the DEX-I + SMLT group at 6 months (295 \u00b1 46 vs. 321 \u00b1 58\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02) and remained lower at 12 months (315 \u00b1 60 vs. 342 \u00b1 70\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.05). Median retreatment-free survival was longer in the combination group (11.2 vs. 8.3 months).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Within the 12-month follow-up period, sequential navigated SMLT performed 4 weeks after dexamethasone implantation was associated with improvements in visual and anatomical outcomes and with a longer retreatment-free interval compared with dexamethasone monotherapy, without additional safety concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004843","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T21:00:12Z","timestamp":1774386012000},"page":"1540-1547","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["EFFICACY OF COMBINED DEXAMETHASONE IMPLANT AND NAVIGATED SUBTHRESHOLD MICROPULSE YELLOW LASER IN DIABETIC MACULAR EDEMA"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3127-9756","authenticated-orcid":false,"given":"Giovanni William","family":"Oliverio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Meduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ingrande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Aragona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261120","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"key":"R2-20261120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000455277","article-title":"Diabetic macular edema","volume":"58","author":"Bandello","year":"2017","journal-title":"Dev Ophthalmol"},{"key":"R3-20261120","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"R4-20261120","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, Sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"R5-20261120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00417-021-05369-9","article-title":"Efficacy and safety of single-dose dexamethasone implantation for patients with persistent diabetic macular edema: a systematic review and meta-analysis","volume":"260","author":"Yuan","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-20261120","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/IAE.0000000000000443","article-title":"Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema","volume":"35","author":"Scaramuzzi","year":"2015","journal-title":"Retina"},{"key":"R7-20261120","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1097\/IAE.0000000000000177","article-title":"Safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema in eyes with good visual acuity","volume":"34","author":"Luttrull","year":"2014","journal-title":"Retina"},{"key":"R8-20261120","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/eye.2014.264","article-title":"Efficacy of subthreshold micropulse laser in the treatment of diabetic macular edema is influenced by pre-treatment central foveal thickness","volume":"28","author":"Mansouri","year":"2014","journal-title":"Eye"},{"key":"R9-20261120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10103-018-2672-9","article-title":"The impact of central foveal thickness on the efficacy of subthreshold micropulse yellow laser photocoagulation in diabetic macular edema","volume":"34","author":"Citirik","year":"2019","journal-title":"Lasers Med Sci"},{"key":"R10-20261120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/tvst.9.10.31","article-title":"Subthreshold micropulse laser in diabetic macular edema: 1-year improvement in OCT\/OCT-angiography biomarkers","volume":"9","author":"Vujosevic","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"R11-20261120","first-page":"729792","article-title":"Stimulation with a micropulse laser induces heat shock protein expression in ARPE-19 cells","volume":"2015","author":"Inagaki","year":"2015","journal-title":"J Ophthalmol"},{"key":"R12-20261120","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/09298673113209990030","article-title":"Subthreshold laser therapy for diabetic macular edema: metabolic and safety issues","volume":"20","author":"Vujosevic","year":"2013","journal-title":"Curr Med Chem"},{"key":"R13-20261120","first-page":"3978514","article-title":"Evaluation of navigated laser photocoagulation (Navilas 577+) for the treatment of refractory diabetic macular edema","volume":"2018","author":"Kato","year":"2018","journal-title":"J Ophthalmol"},{"key":"R14-20261120","doi-asserted-by":"crossref","first-page":"1553311","DOI":"10.3389\/fendo.2025.1553311","article-title":"Evaluating the efficacy of subthreshold micropulse laser combined with anti-VEGF drugs in the treatment of diabetic macular edema: a systematic review and meta-analysis","volume":"16","author":"Jiang","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R15-20261120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5301\/ejo.5001000","article-title":"Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema","volume":"28","author":"Moisseiev","year":"2018","journal-title":"Eur J Ophthalmol"},{"key":"R16-20261120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40942-024-00585-x","article-title":"Short pulse grid and subthreshold micropulse laser (the sandwich grid) plus intravitreal ranibizumab for the treatment of diabetic macular edema","volume":"10","author":"Peroni","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"R17-20261120","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.3390\/ijms23147585","article-title":"The role of intravitreal corticosteroids in the treatment of DME: predictive OCT biomarkers","volume":"23","author":"Munk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R18-20261120","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/bjo-2024-325665","article-title":"Biomarkers of risk of switching to dexamethasone implant for the treatment of diabetic macular oedema in real clinical practice: a multicentric study","volume":"109","author":"Ruiz-Medrano","year":"2025","journal-title":"Br J Ophthalmol"},{"key":"R19-20261120","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.3390\/jcm10143134","article-title":"Subthreshold micropulse laser modulates retinal neuroinflammatory biomarkers in diabetic macular edema","volume":"10","author":"Frizziero","year":"2021","journal-title":"J Clin Med"},{"key":"R20-20261120","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1097\/IAE.0000000000000177","article-title":"Safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema in eyes with good visual acuity","volume":"34","author":"Luttrull","year":"2014","journal-title":"Retina"},{"key":"R21-20261120","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/1120672120915169","article-title":"Subthreshold yellow micropulse laser for treatment of diabetic macular edema: comparison between fixed and variable treatment regimen","volume":"31","author":"Donati","year":"2021","journal-title":"Eur J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:00:12Z","timestamp":1795140012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004843","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}